Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TD. Faith my friend. It’s a powerful tool.
Let’s pour it into the results of very ill patients hanging by a thread to be cured of the disease and get up and walk out of the hospital within a week. This news will travel fast
Next week is my guess. 7 sites in US
The MoA here will be the winner for Covid.
Three in one drug will bring the severe consequences of the virus to its knees
You may be right but just like the mega millions - if you don’t play you don’t win. Anything can happen at anytime in biotech
That’s fine Max. But overall in the long run for Covid this is good news. The trial will be expedited so when it starts next week and we see patients clearing symptoms and leaving hospitals much earlier on their own....this could jump to priority review a d also Emergency Authorization making billions very quickly. Great nees
Interesting. Not too long ago at all.
An extremely positive short CV trial is a big deal. The vaccine is very far from being the savior due to such limited data and resources to roll out on top. I know two nurses who received the vaccine and they know 2 others who have contracted Covid 3 weeks later after receiving first dose. I believe we see an update on data soon showing cases like that as I k ow they are being tracked for big pharma to understand real life data.
Back to my point, if B can stop death that will truly be the silver bullet to this pandemic. A very potent therapeutic for the next 2years and beyond while they get the vaccines rolled out. I bet 40% of this world or more will not get it. Leaving Brilacidin as a blockbuster.
News of great results in this very dark stage can take this price to unthinkable levels IMO. It’s my hope atleast.
Stimulus passed. Govt will not shit down.
IPix will release news tomorrow on trial plans.
The good news is this trial is not like Kevetrin phase 1. Lol. This should go fast and news or results of people’s lives being saved will travel fast in hospitals.
Great Post.
Blue Sky! Let’s GO Leo. There is zero competition and nothing approved while B sits at phase 3 ready.
There was an Arizona hospital with every ICU bed filled with Covid severe case. Resp Fail on the chalk board for all 26 beds. Just one example.
The last sentence makes me think Leo was contacted by a few additional locations. I think the first handful are ready to roll. He is adding on to expedite.
I hope he is trying to reach UK in hopes of PR on positive results on new strain.
If we start dosing severe cases and those patients walk out in a week we are going to hit paydirt imo.
Hoping to get into Scotland to fight new variant strain. That is good PR
FDA Grants IND Approval for Phase 2 Clinical Trial of Innovation Pharmaceuticals’ Brilacidin for Treating COVID-19
December 21, 2020 07:00 ET | Source: Innovation Pharmaceuticals Inc.
Brilacidin’s potent in vitro inhibition of the Washington and Italian strains of SARS-CoV-2 support its potential to inhibit emerging coronavirus mutations (variants), such as those in the United Kingdom, Denmark and South Africa
120-patient trial to be conducted at U.S. and international clinical sites
Primary endpoint time to sustained recovery through Day 29
WAKEFIELD, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company developing Brilacidin, a Host Defense Protein (HDP) mimetic representing a new class of drug with antiviral, anti-inflammatory and anti-bacterial properties, is pleased to announce that the U.S. Food and Drug Administrations (FDA) has approved the Company’s Investigational New Drug (IND) application to proceed with initiation of a Phase 2 clinical trial of Brilacidin in hospitalized patients with COVID-19.
Brilacidin has been shown in vitro to be effective against different SARS-CoV-2 strains (Washington and Italian), as well as multiple human coronaviruses, making it less likely to be affected by emerging mutations (in the United Kingdom, Denmark and South Africa) and further differentiating the drug from other COVID-19 treatments in development today.
With its unique HDP mimetic properties, Brilacidin has potential to exert antiviral activity across SARS-CoV-2 variants. The sudden emergence of highly contagious new variants of the coronavirus illuminates the urgent need for drugs, like Brilacidin, with a different mechanism of action from current antivirals to get this resilient virus under control.
The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled, multi-national, multi-center study expected to enroll approximately 120 patients with moderate-to-severe COVID-19. The trial’s primary endpoint is time to sustained recovery through Day 29 based on the National Institute of Allergy and Infectious Diseases (NIAID) Adaptive COVID-19 Treatment Trial (ACTT) clinical status ordinal scale. The Company will now complete site initiation visits and contracts to add additional clinical sites to the study.
“It’s clear from comments of infectious disease experts like Dr. Anthony Fauci and recent news reports on emerging COVID-19 variants that we are not out of the woods yet with the coronavirus, by any stretch of the imagination. Even with vaccines starting to be rolled-out, it is going to be many more months for them to reach the masses and potentially years before vaccines are available worldwide,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “There is now and will be into the foreseeable future a real need for new therapeutics to treat people who contract the infection. We have great hopes Brilacidin will emerge as a novel therapeutic to help fight the global pandemic.”
Excellent News. Finally.
If Leo can move UC oral trial into the clinic it would be extremely helpful and lucrative if successful.
The CRO and hospitals are waiting for go ahead. This will move fast based on the emergency and surge we are experiencing.
I pray B sends every patient home healthy. A 60% rate pays 425 million. Let’s see 100%
Here is bar:
CD24Fc, in September that showed a 60% higher probability of improvement for patients suffering severe or critical COVID-19 when compared to placebo. The risk of death or respiratory failure was also reduced by more than 50%,
425 million price tag if we can produce results like that. IMO.
Drink fluids and eat healthy as much as you can! Rest but also move. Get better soon! IPIX.
NJ Mary Jane. Paul to be a cashier. That’s atleast a .0003 increase.
Interesting deal terms.
Merck & Co. is buying the biopharmaceutical company OncoImmune, which has reported positive results from a late-stage study of a coronavirus therapeutic candidate, for $425 million in cash.
The acquisition is the big drugmaker's latest in its catch-up in the most important vaccine and treatment chase in modern history. Earlier Monday, AstraZeneca PLC and the University of Oxford said their Covid-19 vaccine was as much as 90% effective in preventing infections without serious side effects in large clinical trials, and a shot created by Moderna Inc. and one jointly made by Pfizer Inc. and BioNTech SE were found to be more than 90% effective in their own late-stage trials.
Under the deal, expected to close by the end of the year, OncoImmune shareholders would be eligible for milestone- and sales-based payments, the companies said Monday. OncoImmune will also spin off an entity involving certain rights and assets unrelated to the Covid-19 treatment to a new entity owned by existing shareholders before the acquisition, with Merck investing $50 million and becoming a minority shareholder in it, the companies added.
Patients with severe or critical Covid-19 who were treated with a single dose of OncoImmune's therapeutic candidate, known as CD24Fc, had a 60% higher probability of improvement than those treated with the placebo, OncoImmune said of its interim analysis of data from 203 participants, or 75% of the planned enrollment in its phase 3 clinical trial. The dose reduced the risk of death or respiratory failure by more than 50%, the Rockville, Md., company added.
Merck, based in Kenilworth, N.J., is a longtime maker of vaccines and antivirals, including human papillomavirus shot Gardasil. The company in September said it had begun testing one of its experimental Covid-19 vaccine candidates in healthy volunteers. It laid out a Covid-19 vaccine program in late May, at a time when several rivals had developed vaccines and begun testing them on healthy volunteers.
For the vaccine, Merck in May said it was acquiring privately held Austrian company Themis Bioscience. The vaccine was developed by the French research nonprofit Institut Pasteur and licensed to Themis. Merck's other coronavirus vaccine effort takes the form of a partnership with the scientific-research organization IAVI, whose experimental vaccine uses the same technology that is the basis for Merck's Ebola Zaire virus vaccine.
Health authorities have eyed vaccines as the antidote needed for the world to begin returning to normal. They are crucial to ensure that enough people are protected against the virus so it can't spread easily, even to those who aren't immune. Some 200 Covid-19 vaccines are in development around the world, according to the World Health Organization, each one promising to protect people from the deadly coronavirus and allow them to go back to work and school. Nearly 50 candidates, based on different technologies, are in clinical trials.
It all begins with human data. The trial will start in December. An easy nasal spray containing Brilacidin may be interesting for common cold.
Things will start heating up. I look forward to this trial beginning. And B oral for UC in q1
Agree. Prior trial starts the same game. Lots of negative noise.
Actually. If you look at ABIO. They submitted an IND for phase 2 around Sept 23rd and received acceptance October 8th. They just received a fast track designation today. They say results will be released from a 100 patient phase 2b trial in second quarter.
We may be on that time frame. I’ll need to research the types of trials their drug has been thru.
I have a feeling Leo has a good PR strategy lined up. Aspire will not deflate the run and increase in value. Fingers crossed. Start of trial is a huge milestone and I expect to see results fairly quick. IMO.
Great info and opinion. It’s beyond my pay as well. I’ll share intel as I continue to research the mRNA method.
To me. Step by step will be key. Brilacidin needs to start the Covid trial. Step one. Step 2 get results and I’m hopeful they are positive due to triple MoA for severe cases.
That alone will create value.
Cybermich. Do you have a resource for that statement. Very interesting if true.
I’m doing a skim on mRNA and past, trying to understand what it does to the human body and how it works.
I saw that. Thx for posting. I’m excited to see Brilacidin results.
Good post. Facts. I’m hopeful due to this being Covid related the fda will grant application approval in a lessor time frame
We shall see
Good to know. It’s amazing how everything is against a small bio! Time / money / resources.... but it just takes that one interested party to make a splash.
Good news today about additional research showing B kills viruses and bacteria with a silver bullet. No matter the mutation. Good news.
IND this week, let’s hope the fda spins it around much quicker than 30 days which I’m hopeful. Across seas should move much faster. IMO.
Thank you Lady! Sun spotter. You know all of this. You’ve been here for many years.
Here is a deck with results from 2b trial
https://static1.squarespace.com/static/5715352e20c647639137f992/t/583f8286d2b85731b8713a36/1480557192947/A-Randomized-Double-Blind-Study-Comparing-Single-Dose-and-Short-Course-Brilacidin-to-Daptomycin-in-the-Treatment-of-Acute-Bacterial-Skin-Skin-Structure-Infections-ABSSSI1.pdf
Here is clinical trial phase 2 ran by IPIX in 2015
https://clinicaltrials.gov/ct2/show/study/NCT02052388?term=Brilacidin&cond=ABSSSI&cntry=US&draw=2&rank=1
A vaccine takes years to truly understand.
In this quick study they are injecting the vaccine to cohorts and basically saying go live your life The world is masked and social distancing. Out of 330 million Americans only 10 million documented cases.
Look in the Southern Hemisphere. The flu is basically non existent. Due to masks and distancing. Etc.
The only true way to see how effective this drug is imo is to introduce or infect the patients with Covid to see the response.
A solid therapeutic will be needed!
Good post. It is what it is as the President says.
When Leo can ink a solid deal.
Wait for first human dosing. Then a few weeks later when B pops the Covid like a balloon.....we shall see life changing moves from IPIX
Thanks Farrell. Appreciate your thoughts
It will be interesting to say the least.